DNTH
$77.76-2.24 (-2.80%)
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includ...
Recent News
Wedbush Keeps Outperform on Dianthus Therapeutics, Inc. (DNTH), Highlights Potential of Claseprubart in CIDP
We recently compiled a list of the Top 10 Boring Stocks That Make Money. Dianthus Therapeutics, Inc. (NASDAQ:DNTH) is among the most boring stocks. TheFly reported on March 12 that Wedbush raised its price target on DNTH to $103 from $80 while reiterating an Outperform rating. The firm updated its estimates following the company’s recent […]
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions.
Dianthus Therapeutics Hits Early “Go” in CAPTIVATE Phase 3 CIDP Trial, Drops 600 mg Arm
Dianthus Therapeutics (NASDAQ:DNTH) said it has made an “early go” decision to continue its CAPTIVATE Phase 3 trial evaluating claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), based on a planned interim responder analysis from Part A of the ongoing pivotal study. Management
Dianthus Therapeutics (DNTH) Is Up 30.8% After Upsized Raise And Early Phase 3 “Go” Decision
Earlier this week, Dianthus Therapeutics completed an upsized follow-on offering raising about US$625.00 million in common stock and pre-funded warrants, shortly after reporting wider 2025 losses and lower revenue. At the same time, the company announced an early “go” decision in its Phase 3 CAPTIVATE trial of claseprubart in CIDP, suggesting the drug’s profile was strong enough to justify accelerating development plans and expanding its neuromuscular pipeline. We’ll now examine how the...
Guggenheim Reiterates Buy Rating for Dianthus Therapeutics (DNTH)
Dianthus Therapeutics Inc. (NASDAQ:DNTH) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On March 4, Guggenheim increased the price target on Dianthus Therapeutics Inc. (NASDAQ:DNTH) to $200 from $100. The firm maintains its Buy rating on the stock with an upside potential of almost 207%. The adjustment follows […]